biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > FDA Approval of PRX-102 (Elfabrio)

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon May 10, 2023 4:11pm

113 Views

Post# 35441625

RE:RE:FDA Approval of PRX-102 (Elfabrio)

My understanding of xB3 drug development is that, as new chemical entities, the research part of R&D would likely require less work but the preclinical and clinical work could be about the same as other drugs. On the other hand, most xB3 drugs would likely qualify for orphan drug or other expedited advancement considerations.

jd

<< Previous

Bullboard Posts

Next >>

Futures Flat Amid Key Data in Canada and US